Celularity (NASDAQ:CELU) Trading Down 10.4% – Time to Sell?

Shares of Celularity, Inc. (NASDAQ:CELU) traded down 10.4% during mid-day trading on Monday . The stock traded as low as $1.1750 and last traded at $1.20. 183,327 shares changed hands during mid-day trading, an increase of 161% from the average session volume of 70,298 shares. The stock had previously closed at $1.34.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Wall Street Zen cut shares of Celularity from a “hold” rating to a “sell” rating in a research report on Friday, September 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celularity in a report on Wednesday, October 8th. Finally, WBB Securities raised Celularity from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Tuesday, September 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

Celularity Trading Down 1.3%

The business has a 50 day moving average of $1.70 and a two-hundred day moving average of $2.26. The firm has a market cap of $31.61 million, a P/E ratio of -0.33 and a beta of 0.77.

Celularity (NASDAQ:CELU) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.62. Celularity had a negative net margin of 198.75% and a negative return on equity of 459.57%. The firm had revenue of $5.28 million during the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Valmark Advisers Inc. bought a new stake in shares of Celularity during the second quarter worth approximately $98,000. HB Wealth Management LLC bought a new position in shares of Celularity during the third quarter worth approximately $84,000. Perennial Investment Advisors LLC acquired a new stake in Celularity during the 3rd quarter worth approximately $28,000. Yorkville Advisors Global LP acquired a new stake in Celularity during the 3rd quarter worth approximately $207,000. Finally, Vanguard Group Inc. boosted its stake in Celularity by 35.3% in the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after purchasing an additional 176,518 shares during the period. Institutional investors and hedge funds own 19.02% of the company’s stock.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.